[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK3288944T3 - Imidazopyrazinoner som pde1-inhibitorer - Google Patents

Imidazopyrazinoner som pde1-inhibitorer Download PDF

Info

Publication number
DK3288944T3
DK3288944T3 DK16720101.1T DK16720101T DK3288944T3 DK 3288944 T3 DK3288944 T3 DK 3288944T3 DK 16720101 T DK16720101 T DK 16720101T DK 3288944 T3 DK3288944 T3 DK 3288944T3
Authority
DK
Denmark
Prior art keywords
imidazopyrazinones
pde1 inhibitors
pde1
inhibitors
Prior art date
Application number
DK16720101.1T
Other languages
English (en)
Inventor
Mikkel Jessing
Karsten Juhl
Morten Langgård
Paulo Jorge Vieira Vital
Jan Kehler
Lars Kyhn Rasmussen
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Application granted granted Critical
Publication of DK3288944T3 publication Critical patent/DK3288944T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK16720101.1T 2015-04-30 2016-04-29 Imidazopyrazinoner som pde1-inhibitorer DK3288944T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA201500261 2015-04-30
DKPA201500666 2015-10-29
DKPA201600202 2016-04-04
PCT/EP2016/059583 WO2016174188A1 (en) 2015-04-30 2016-04-29 Imidazopyrazinones as pde1 inhibitors

Publications (1)

Publication Number Publication Date
DK3288944T3 true DK3288944T3 (da) 2019-07-22

Family

ID=55910242

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16720101.1T DK3288944T3 (da) 2015-04-30 2016-04-29 Imidazopyrazinoner som pde1-inhibitorer

Country Status (41)

Country Link
US (4) US20160318939A1 (da)
EP (1) EP3288944B1 (da)
JP (1) JP6663930B2 (da)
KR (1) KR102605759B1 (da)
CN (1) CN107531714B (da)
AU (1) AU2016256573B2 (da)
BR (1) BR112017023182B1 (da)
CA (1) CA2983563A1 (da)
CL (1) CL2017002719A1 (da)
CO (1) CO2017010399A2 (da)
CY (1) CY1121806T1 (da)
DK (1) DK3288944T3 (da)
DO (1) DOP2017000254A (da)
EA (1) EA031946B1 (da)
EC (1) ECSP17072228A (da)
ES (1) ES2735422T3 (da)
GE (1) GEP20207058B (da)
GT (1) GT201700223A (da)
HK (1) HK1252098B (da)
HR (1) HRP20191180T1 (da)
HU (1) HUE044244T2 (da)
IL (1) IL255316B (da)
JO (1) JO3627B1 (da)
LT (1) LT3288944T (da)
MA (1) MA41977B1 (da)
ME (1) ME03414B (da)
MX (1) MX2017013785A (da)
MY (1) MY182382A (da)
PE (1) PE20180121A1 (da)
PH (1) PH12017501990B1 (da)
PL (1) PL3288944T3 (da)
PT (1) PT3288944T (da)
RS (1) RS59051B1 (da)
RU (1) RU2712219C2 (da)
SG (1) SG11201708822PA (da)
SI (1) SI3288944T1 (da)
TN (1) TN2017000428A1 (da)
TW (1) TWI695838B (da)
UA (1) UA123050C2 (da)
WO (1) WO2016174188A1 (da)
ZA (1) ZA201706847B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201629064A (zh) 2014-10-10 2016-08-16 H 朗德貝克公司 作爲pde1抑制劑之三唑並吡酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商H 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
CN109843884B (zh) 2016-10-18 2022-03-04 H.隆德贝克有限公司 作为pde1抑制剂的咪唑并吡嗪酮、吡唑并嘧啶酮和吡唑并吡啶酮
EP3532053A1 (en) 2016-10-28 2019-09-04 H. Lundbeck A/S Combination treatments comprising administration of imidazopyrazinones
BR112018013247A2 (pt) * 2016-10-28 2018-12-04 H Lundbeck As tratamentos de combinação compreendendo imidazopirazinonas para o tratamento de distúrbios psiquiátricos e/ou cognitivos
JOP20190126A1 (ar) 2016-12-22 2019-05-28 H Lundbeck As بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1
EP3562828A1 (en) 2016-12-28 2019-11-06 Dart NeuroScience LLC Substituted pyrazolopyrimidinone compounds as pde2 inhibitors
KR20200108419A (ko) 2017-11-27 2020-09-18 다트 뉴로사이언스, 엘엘씨 Pde1 억제제로서의 치환된 푸라노피리미딘 화합물
AR113926A1 (es) * 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
WO2019121840A1 (en) 2017-12-20 2019-06-27 H. Lundbeck A/S Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors
IT202200024948A1 (it) * 2022-12-05 2024-06-05 Angelini Pharma S P A Composti attivatori dei canali potassio KV7.2/KV7.3

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB973361A (en) 1960-05-11 1964-10-28 Ciba Ltd Pyrazolo-pyrimidines and process for their manufacture
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
EP1626971B1 (de) 2003-05-09 2011-08-10 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- und 6-alkylmethyl-substituierte pyrazolopyrimidine
ES2328833T3 (es) * 2004-04-02 2009-11-18 Osi Pharmaceuticals, Inc. Inhibidores de proteina quinasa heterobiciclicos con anillo 6,6-biciclico.
EP1828192B1 (en) * 2004-12-21 2014-12-03 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20080194592A1 (en) * 2005-08-23 2008-08-14 Intra-Cellular Therapies, Inc. Organic Compounds
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
EP2089034A4 (en) 2006-12-05 2010-07-28 Intra Cellular Therapies Inc NEW USES
PL2152712T3 (pl) 2007-05-11 2012-05-31 Pfizer Związki aminoheterocykliczne
CA2706986A1 (en) 2007-11-30 2009-06-04 Elbion Gmbh Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
US9079905B2 (en) 2008-09-08 2015-07-14 Boehringer Ingelheim International Gmbh Compounds for the treatment of CNS disorders
MA32941B1 (fr) * 2008-12-06 2012-01-02 Intra Cellular Therapies Inc Composes organiques
TWI404721B (zh) * 2009-01-26 2013-08-11 Pfizer 胺基-雜環化合物
EP2440234A4 (en) 2009-06-10 2013-11-06 Univ New York IMMUNOLOGICAL TARGETING OF PATHOLOGICAL TAU PROTEINS
JP5879336B2 (ja) 2010-05-31 2016-03-08 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
PL3042917T3 (pl) 2010-08-12 2018-07-31 Eli Lilly And Company Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie
RU2603140C2 (ru) * 2010-09-20 2016-11-20 Айронвуд Фармасьютикалз, Инк. Соединения имидазотриазинона
US20130196986A1 (en) 2010-09-21 2013-08-01 Marc Labroli Triazolopyrazinones as p2x7 receptor antagonists
JO3089B1 (ar) 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
US9499610B2 (en) 2011-04-08 2016-11-22 H. Lundbeck A/S Antibodies specific to pyroglutamated Aβ
JP6051210B2 (ja) 2011-06-10 2016-12-27 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
CN106905324B (zh) * 2011-10-10 2018-09-25 H.隆德贝克有限公司 具有咪唑并吡嗪酮骨架的pde9抑制剂
EP2807163B1 (en) 2012-01-26 2017-03-22 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone
JP2013166727A (ja) 2012-02-16 2013-08-29 Dainippon Sumitomo Pharma Co Ltd ジヒドロイミダゾピラジノン誘導体
DK2861603T3 (da) 2012-06-18 2019-03-04 Dart Neuroscience Cayman Ltd 6-benzyl-6H-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-on og 6-benzyl-[1,2,4]triazolo[1,5-c]pteridin-5(6H)-on-derivater som PDE1-inhibitorer til behandling af fx neurologiske forstyrrelser
EP2970279B1 (en) 2013-03-15 2020-09-16 Intra-Cellular Therapies, Inc. Organic compounds
JP5783297B2 (ja) 2013-08-06 2015-09-24 株式会社デンソー 力学量センサ
EP3107897A1 (en) 2014-02-19 2016-12-28 H. Lundbeck A/S 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
JP5797815B1 (ja) 2014-06-27 2015-10-21 細田建設株式会社 後施工アンカー及びその施工方法
US20160083400A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic guanidine derivative
JP2017527606A (ja) 2014-09-18 2017-09-21 サノビオン ファーマシューティカルズ インクSunovion Pharmaceuticals Inc. 三環系誘導体
US20160083391A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic piperazine derivative
TW201629064A (zh) 2014-10-10 2016-08-16 H 朗德貝克公司 作爲pde1抑制劑之三唑並吡酮
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
WO2016147659A1 (en) 2015-03-16 2016-09-22 Sumitomo Dainippon Pharma Co., Ltd. Bicyclic imidazolo derivative
TW201643167A (zh) 2015-04-22 2016-12-16 H 朗德貝克公司 作爲pde1抑制劑之咪唑並三酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
EA201890256A1 (ru) 2015-08-12 2018-06-29 Х. Лундбекк А/С 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1
AR107456A1 (es) 2016-02-12 2018-05-02 Lilly Co Eli Inhibidor de pde1
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商H 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
CN109843884B (zh) 2016-10-18 2022-03-04 H.隆德贝克有限公司 作为pde1抑制剂的咪唑并吡嗪酮、吡唑并嘧啶酮和吡唑并吡啶酮
EP3532053A1 (en) 2016-10-28 2019-09-04 H. Lundbeck A/S Combination treatments comprising administration of imidazopyrazinones
BR112018013247A2 (pt) 2016-10-28 2018-12-04 H Lundbeck As tratamentos de combinação compreendendo imidazopirazinonas para o tratamento de distúrbios psiquiátricos e/ou cognitivos

Also Published As

Publication number Publication date
HRP20191180T1 (hr) 2019-10-04
ME03414B (me) 2020-01-20
BR112017023182A2 (da) 2018-10-02
CY1121806T1 (el) 2020-07-31
MA41977A (fr) 2018-07-23
MY182382A (en) 2021-01-22
TWI695838B (zh) 2020-06-11
KR20170140216A (ko) 2017-12-20
US10858362B2 (en) 2020-12-08
US20190062335A1 (en) 2019-02-28
US20210238182A1 (en) 2021-08-05
IL255316B (en) 2021-10-31
CO2017010399A2 (es) 2018-01-05
JP2018514552A (ja) 2018-06-07
US20160318939A1 (en) 2016-11-03
MX2017013785A (es) 2018-03-27
SG11201708822PA (en) 2017-11-29
HUE044244T2 (hu) 2019-10-28
SI3288944T1 (sl) 2019-08-30
BR112017023182B1 (pt) 2023-10-31
CN107531714B (zh) 2019-07-19
CL2017002719A1 (es) 2018-04-20
PH12017501990A1 (en) 2018-03-26
JO3627B1 (ar) 2020-08-27
ECSP17072228A (es) 2018-02-28
RU2017137514A (ru) 2019-05-31
EP3288944B1 (en) 2019-06-12
RU2712219C2 (ru) 2020-01-27
PE20180121A1 (es) 2018-01-18
PL3288944T3 (pl) 2019-11-29
HK1252098A1 (zh) 2019-05-17
CA2983563A1 (en) 2016-11-03
US10011606B2 (en) 2018-07-03
EA031946B1 (ru) 2019-03-29
EA201792157A1 (ru) 2018-03-30
ZA201706847B (en) 2019-01-30
JP6663930B2 (ja) 2020-03-13
ES2735422T3 (es) 2019-12-18
PH12017501990B1 (en) 2018-03-26
CN107531714A (zh) 2018-01-02
EP3288944A1 (en) 2018-03-07
AU2016256573A1 (en) 2017-12-14
TN2017000428A1 (en) 2019-04-12
LT3288944T (lt) 2019-07-25
MA41977B1 (fr) 2019-08-30
DOP2017000254A (es) 2018-01-15
GEP20207058B (en) 2020-01-27
GT201700223A (es) 2018-12-19
RS59051B1 (sr) 2019-08-30
KR102605759B1 (ko) 2023-11-23
AU2016256573B2 (en) 2019-11-21
US11472810B2 (en) 2022-10-18
PT3288944T (pt) 2019-07-19
RU2017137514A3 (da) 2019-07-17
WO2016174188A1 (en) 2016-11-03
TW201700477A (zh) 2017-01-01
HK1252098B (zh) 2020-02-07
UA123050C2 (uk) 2021-02-10
US20170291903A1 (en) 2017-10-12
IL255316A0 (en) 2017-12-31

Similar Documents

Publication Publication Date Title
DK3277677T3 (da) 1-cyano-pyrrolidinforbindelser som usp30-hæmmere
DK3105218T3 (da) Cyclopropylaminer som lsd1-inhibitorer
DK3105226T3 (da) Cyclopropylaminer som lsd1-inhibitorer
DK3283625T3 (da) Nukleasemedieret genomeditering
DK3371190T3 (da) Heterocykliske forbindelser som pi3k-gamma-inhibitorer
DK3442972T3 (da) Bromdomænehæmmere
DK3072835T3 (da) Fremgangsmåde til fremføring
DK3305788T3 (da) Janus-kinase-hæmmer
BR112016030697A2 (pt) inibidores da desmetilase-1 específica da lisina
DK3277719T3 (da) Polypeptider
DK3288944T3 (da) Imidazopyrazinoner som pde1-inhibitorer
BR112017000042A2 (pt) inibidores de desmetilase-1 lisina-específica
MA44006A (fr) Inhibiteur pde1
DK3310450T3 (da) Olie-vand-separator
DK3458460T3 (da) Imidazoler som histondemethylase-inhibitorer
DK3116475T3 (da) Dopa-decarboxylasehæmmersammensætninger
DK3256462T3 (da) Substituerede 2-thioimidazolyl-carboxamider som skadedyrsbekæmpelsesmiddel
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
DK3341379T3 (da) EZH2-hæmmere
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
DK3270930T3 (da) Præeklampsi
DK3296597T3 (da) Krydshovedmotor
DK3717488T3 (da) Substituerede furanopyrimidinforbindelser som pde1-inhibitorer
DK3265394T3 (da) Fremgangsmåde til emballering